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Lung Cancer Cells A549 
 
 
Abstract 
 
 
by Weizhou Yue 
 
University of the Pacific 
2017 
 
 
 Proteins are large biomolecules that have great therapeutic potential in treating 
many human diseases.  However, chemical/enzymatic degradation, denaturation, and 
poor penetration into cells are some of the challenges for clinical use of intracellular 
proteins. 
 Previously, our group has developed cationic lipid-coated magnesium phosphate 
nanoparticle (LP MgP NP-CAT) formulations to enhance the intracellular delivery of the 
negatively charged protein catalase.  The goal of the current research is to develop a 
formulation to deliver cytochrome c (CytC), a positively charged protein into lung cancer 
cells A549.  Specifically, this thesis research prepares and tests liposome-coated 
magnesium phosphate nanoparticle for delivery of cytochrome c (CytC LP/MgP). 
 CytC LP/MgP was designed, prepared and characterized, showing that it had an 
average diameter around 150 nm and ζ-potential around +30 mV.  The morphology of 
CytC LP/MgP was validated by transmission electron microscopy. 
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 CytC LP/MgP successfully led to the attachment of CytC to A549 cells, as 
supported by fluorescence imaging.  Intracellular delivery of CytC alleviated the 
cytotoxicity of cationic lipids in A549 cells, as suggested by the MTS assay on cell 
viability, which could facilitate the clinical use of cationic lipids in drug delivery 
systems.
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Chapter 1: Current Development of Devices for Intracellular Protein Delivery 
1.1 Introduction 
Proteins represent the most diverse molecules in biology.  In the past thirty years, 
proteins purified from natural sources or produced from recombinant biotechnology have 
found a plethora of applications in modern medicine, including supplementation or 
modulation of a biological function, targeting specific cell types, vaccination, and 
diagnostics [1].  Up till now, more than a hundred proteins have been approved by FDA 
as therapeutic or diagnostic agents in USA.  Compared to small molecule drugs, proteins 
as therapeutics agents carry the potential advantages of exerting more complicated 
activities, higher specificity, higher bio-compatibility and, in average, shorter time for 
drug development/approval [1].  With accelerated understanding of the cellular functions 
of proteins after the completion of the human genome project, the role of proteins in 
modern medicine is expected to expand remarkably in the next decade [1]. 
Nevertheless, one common challenge of developing protein-based medications is 
to achieve an adequate pharmacokinetic profile, including long enough half-life in blood 
circulation and sufficient distribution to the target site [2].  After administration, native 
proteins are prone to enzymatic degradation and hepatic/renal elimination while 
circulating in the blood, and are too large to diffuse into cells.  Therefore, the 
development of technologies to enhance the delivery of proteins to their target site is 
critical for capitalizing on their potential as future therapeutic agents.
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In this chapter, the current development of devices for intracellular protein 
delivery is reviewed and summarized. 
1.2 Microinjection 
Single-cell microinjection has been successfully used to deliver exogenous 
proteins, cDNA constructs, peptides, drugs and particles into transfection-challenged 
cells through a glass micropipette.   Due to its advantage of precise control over dosage 
and timing, microinjection has been widely used in studies on primary cultured cells, 
transgenic animal production, in vitro fertilization and RNA interference. 
The p53 tumor suppressor is a transcription factor frequently mutated in human 
malignancies.  Tumor-derived p53 missense mutants are defective in sequence-specific 
DNA binding and fail to activate p53 target genes, Abarzua et al. showed that 
microinjection of mAb PAb421, which was shown previously to restore DNA binding to 
selected p53 mutants in vitro, restored the transcription activation function of the resident 
mutant p53 in human SW480 colorectal carcinoma cells (arg to his 273, pro to ser 309) 
[3].  The results supported the concept of restoring wild-type function to mutant p53 as a 
strategy for cancer therapy. 
1.3 Electroporation 
Electroporation applies an electric current across a cell membrane to perform 
temporary “pores” formation, which allow exogenous molecules in the medium to enter 
either the cytoplasm or the nucleus, thereby transfecting or transforming the cell. 
In vascular smooth muscle cells, rapid tyrosine phosphorylation of phospholipase 
C-γ1 (PLC-γ1) is the mechanism of how the binding of angiotensin II occupancy of the 
angiotensin II receptor AT1 mobilizes calcium from the cytoplasm to eventually cause the 
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contraction of the smooth muscle cell.  Marrero et al. reported that intracellular delivery 
of pp60c-src antibodies inhibited the angiotensin II phosphorylation of PLC-γ1 in cultured 
rat aortic smooth muscle (RASM) cells [4].  These data provided the first evidence for a 
direct involvement of pp60c-src kinase in angiotensin II-mediated PLC-γ1 
phosphorylation. 
1.4 Mesoporous Silica Nanoparticles 
Mesoporous silica nanoparticles with high surface areas (>800 m2/g) and tunable 
pore diameter (2-10 nm) were synthesized to develop a variety of new delivery 
formulations, where different guest molecules, such as small molecular drugs, fluorescent 
imaging agents, and proteins, could be absorbed into the mesopores and released into 
solutions later. 
It is known that cytochrome c (CytC) catalyzes the oxidation of 2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulfonate) (ABTS) by hydrogen peroxide.  Slowing et al. found 
that MCM-41-type mesoporous silica nanoparticle (MSN) with a large average pore 
diameter (5.4 nm) could serve as a transmembrane delivery vehicle for controlled release 
of the protein CytC in live human cervical cancer cells (HeLa), which find many 
important pharmaceutical applications as therapeutics and diagnostic agents [5]. 
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Fig. 1.1. Schematic representation of the MSN transporting cytochrome c through the cell 
membrane and releasing the protein into the cytoplasm [5]. 
 
 
 
1.5 Cell Penetrating Peptides (CPPs) 
Short peptides isolated from protein-transduction domains (cell penetrating 
peptides or CPPs) of various protein types allow the intracellular delivery of conjugated 
(or fused) biomolecules.  A wide range of cargos such as antigenic peptides, peptide 
nucleic acids, antisense oligonucleotides, full-length proteins, or even nanoparticles and 
liposomes have been intracellularly delivered by this way. 
Räägel et al. presented the characterization of intracellular trafficking of 3 
different CPP–avidin complexes (transportan-, nona-arginine- and Tat-avidin) in Cos-7 
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cells related to different endocytic routes during CPP-cargo internalization, which proved 
characteristic properties of CPPs chose pathways to gain entry to cells [6]. 
1.6 Cationic Liposomes 
Liposomes are artificial vesicles composed essentially of mostly phospholipids 
and have been reported to serve as immunological adjuvants and drugs carriers.  
Furthermore, cationic liposomes are currently used as non-viral delivery systems, because 
DNA or proteins that are negatively charged readily form a complex with cationic 
liposomes via electrostatic interactions.  
1.6.1 The Delivery System Composed of TFA-DODAPL and DOPE 
Zelphati et al. reported a cationic liposomal formulation composed of a new 
trifluoroacetylated lipopolyamine (TFA-DODAPL) and dioleoyl 
phosphatidylethanolamine (DOPE), successfully delivered antibodies, dextran sulfates, 
phycobiliproteins, albumin, and enzymes (β-galactosidase and proteases) into the 
cytoplasm of numerous adherent and suspension cells [7].  This advanced protein 
delivery system represented a powerful tool for functional protein delivery and might 
have potential for therapeutic applications. 
1.6.2 Nanoparticle Composed of DOTAP/DOPE and APOA-I 
Amphiphilic residues, such as cell penetrating peptides (CPPs), have been 
conjugated to non-lipophilic proteins such as CytC and GFP to anchor the proteins into 
the lipid bilayer of nanoparticles (NP).  For example, Kim et al. reported that a NP 
composed of lipid (DOTAP/DOPE) and apolipoprotein (APOA-I) delivered 
intracellularly-acting proteins (e.g. CytC or GFP) into non-small cell lung tumors.  This 
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nanoparticle holds great potential for the effective delivery of non-lipophilic proteins for 
cancer therapy [8]. 
 
 
 
 
Fig. 1.2. Schematic representation of nanoparticle preparation for protein delivery [8]. 
 
 
 
1.6.3 Commercially Available Cationic Lipids 
Zuris et al. reported that cationic lipids that are commonly used as nucleic acid 
transfection reagents could potently deliver proteins that were fused to negatively 
supercharged molecules (e.g. (-30)GFP-Cre, Cas9:sgRNA complexes) [9].  These 
findings suggested that the intracellular delivery of polyanionic proteins and 
protein:nucleic acid complexes by cationic lipids might expand the research and 
therapeutic applications of proteins. 
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Fig. 1.3. Strategy for delivering proteins into mammalian cells by fusion or non-covalent 
complexation with polyanionic macromolecules and complexation with cationic lipids 
[9]. 
 
 
 
1.6.4 Cationic Liposome Coated-Magnesium Phosphate Nanoparticles (LP/MgP) 
The low efficiency of endosomal escape and the high level of lysosomal 
degradation are major challenges to all protein delivery systems that enter the cells via 
endocytosis.  Our group previously developed liposome-coated magnesium phosphate 
nanoparticle (LP MgP NP-CAT), which is designed to destabilize the endosome and 
release the cargo at lowerd pH, loaded with negatively charged protein that degrades 
hydrogen peroxide in cells.  Intratracheal administration of LP MgP NP-CAT loaded with 
catalase that significantly lowered ROS levels in mouse lungs, demonstrating its great 
promise for protein-based therapy in the clinic [10]. 
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Fig. 1.4. Schematic image representing the LP/MgP for protein delivery [10].  +: Positive 
charges of LP/MgP; MgP NP: magnesium phosphate nanoparticles (MgP); red squares: 
cargo proteins; and gray circles: lipid membranes (LP) consisting of DOTAP/cholesterol. 
 
 
 
1.7 Conclusion 
Although the abovementioned delivery devices display their great promises for 
therapeutic applications, their drawbacks are also noticeable.  Microinjection and 
electroporation require specialized equipment and technical skill to prevent cell damage 
and is not convenient when a large number of cells need to be assessed simultaneously 
for intercellular trafficking; cell penetrating peptides (CPPs) generate too many unwanted 
side effects due to their unintended penetration to untargeted normal cells; nanoparticles 
including mesoporous silica nanoparticles with large pores and commercially available 
MgP NP 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
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cationic liposomes generally suffer from low tolerance of serum, poor endosomal escape, 
and limited in vivo efficacy [9].  Therefore, novel protein delivery systems that could 
minimize these drawbacks would lead the advances of protein-based pharmacotherapy. 
 
 
 
Table 1.1. Reported intracellular protein delivery systems. 
  
Approaches vehicles Cargoes Drawbacks
Microinjection
mAb PAb421
Require specialized equipment and 
expertise to prevent cell damage; 
inconvenient for delivering to a large 
number of cells
Electroporation
pp60c-src antibodies
Highly disruptive, cytotoxic, and 
inefficient
Transportan
Oligoarginine
Tat
Mesoporous Silica Nanoparticles with 
large pores
Degradation in serum, poor 
endosomal escape, limited in vivo 
efficacy
Poor endosomal escape
Degradation in serum, poor 
endosomal escape, limited in vivo 
efficacy
Physicochemical properties limit in 
vivo  application
Excessive side effects
Cell-penetrating 
peptides (CPPs)
Liposomes
Nanoparticles
A trifluoroacetylated lipopolyamine 
(TFA-DODAPL) and dioleoyl 
phosphatidylethanolamine (DOPE)
A nanoparticle (NP) composed of lipid 
(DOTAP/DOPE) and apolipoprotein 
(APOA-I) 
Commercially available cationic lipids
cytochrome c
avidin
antibodies, dextran sulfates, 
phycobiliproteins, albumin, and 
enzymes (β-galactosidase and 
proteases)
intracellular-acting protein drugs 
(GFP, cytochrome c)
negatively supercharged proteins 
((−30)GFP-Cre, Cas9:sgRNA 
complexes)
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Chapter 2: Design of Magnesium Phosphate Nanoparticles with Cationic Lipid 
Coating for Intracellular Delivery of Cytochrome C (CytC LP/MgP) 
2.1 Introduction 
Current non-viral vectors possess several potential advantages, such as ease of 
large-scale production, the capacity to carry large cargos as well as the potential to 
exhibit relatively lower immunogenicity in comparison to viral approaches.  However, 
non-viral vectors typically exhibit relatively lower delivery efficiencies when compared 
to viral approaches.  For non-viral vectors, lower delivery efficiencies (in comparison to 
viral approaches) were observed because of entrapment in endosome/lysosome, 
degradation, and inefficient cellular uptake.  To solve these problems, Olton et al. 
developed a formulation of CaP nanoparticles with cationic lipid-coating because of 
CaP’s biodegradability, biocompatibility, and ease of handling.  CaP increased the 
fraction of the cargo that both successfully escaped from endosomes and effectively 
trafficked to the cytosol.  The cationic lipid-coating of the formulation also helped to 
protect the cargo from denaturation [11]. 
Inspired by this design, our group recently developed a novel delivery system-
magnesium phosphate nanoparticle coated with cationic lipid (LP/MgP) for intracellular 
protein delivery.  Protein cargos were chosen because protein therapeutics have high 
specificity in action, and innate proteins for therapy are well tolerated and less likely to 
elicit immune responses.  Therapeutic protein cargos also enjoy faster clinical 
development and shorter FDA approval time than small-molecule drugs.  Moreover, 
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protein therapeutics are easier to obtain extensive patent protection.  Negatively charged 
protein catalase was complexed with cationic liposome-coated magnesium phosphate 
nanoparticles by electrostatic interaction.  The formulation reduced ROS level by 60% in 
EA.hy926 cells [10]. 
Based on the foregoing, the hypothesis of this thesis project is that liposome-
coated magnesium phosphate nanoparticles (LP/MgP) can also enhance the intracellular 
delivery of positively charged proteins such as cytochrome c (CytC).  CytC can be 
complexed non-specifically and delivered by rehydrated lipids in vitro, where this 
protein-liposome complexation is dependent on high protein concentrations. 
This thesis research proposes to formulate liposome-coated magnesium phosphate 
nanoparticles containing the positively charged cargo protein, cytochrome c (CytC 
LP/MgP).  Such CytC LP/MgP formulation comprises a core of MgP, a coating of 
cationic lipids, and the encapsulated cargo protein cytochrome c. 
 
 
 
 
Fig. 2.1. Diagram of CytC LP/MgP. 
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2.1.1 Lipid – DOTAP 
Kawakami et al. demonstrated that cationic liposomes composed of 
DOTAP/cholesterol accumulated in the lung one minute after intravenous injection [12].  
Cationic liposomes are internalized by endocytosis in these cells.  Notably, fusion of 
liposomes with the endosomal membrane during endosome maturation can facilitate the 
endosomal escape of cationic lipid-delivered cargo [13].  Furthermore, C18 unsaturated 
hydrophobic chains of cationic lipid DOTAP allow DOTAP/cholesterol liposomes to be 
extruded through the 100-nm polycarbonate membrane readily at room temperature.  Last 
but not least, cationic lipids are often mixed with so-called helper lipids, such as dioleoyl 
phosphatidylethanolamine (DOPE) or cholesterol.  The helper lipids would enhance the 
lipid transition from the lamellar phase to a non-lamellar structure, which would improve 
the delivery efficiency [14]. 
However, high cytotoxicity was observed in a concentration-dependent manner 
for DOTAP/cholesterol liposomes.  It is well-known that the cytotoxicity of cationic 
liposomes is due to apoptosis.  Mechanisms of toxicity by cationic liposomes include 
change of mitochondrial membrane potential, generation of reactive oxygen species 
(ROS), dissociation of cytochrome c from the inner mitochondrial membrane, formation 
of the mitochondrial outer membrane permeabilization pore (MOMPP), release of 
cytochrome c, and apoptosis [15].  Therefore, alleviating the toxicity of cationic 
liposomes becomes an important issue for the development of liposomal delivery 
systems. 
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Fig. 2.2. Chemical structure of DOTAP, a commonly used cationic lipid [15]. 
 
 
 
2.1.2 Magnesium Phosphate Nanoparticle (MgP) as the Core of the Proposed 
Formulation 
Calcium phosphate precipitation has been one of the most common techniques to 
transfect cultured cells in biological research.  Roy et al. reported that after calcium 
chloride and sodium phosphate solutions were each dispersed into organic solvents to 
form two separate water-in-oil microemulsions, calcium phosphate precipitates at 100-
120 nm in diameter were reliably generated by mixing two emulsions at low temperature 
[16].  Later, Li et al. reported that when calcium phosphate precipitates were coated with 
sodium citrate, excessive negative surface charges prevented their aggregation.  
Moreover, when such negatively charged calcium phosphate precipitates were mixed 
with cationic liposomes consisting of DOTAP/cholesterol, the cationic liposomes 
spontaneously wrapped around the calcium phosphate precipitates by electrostatic 
interaction to form calcium phosphate nano-precipitates that are coated by concentric 
lipid membranes [17]. 
One remarkable property of these nano-precipitates is that they promptly dissolve 
when the pH decreases from 8 to 5.  Therefore, calcium phosphate precipitates are 
expected to dissolve and turn into a highly concentrated calcium phosphate solution after 
their endocytosis, when they are exposed to the acidic endosomal pH.  The solution 
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would then absorb water because of its high osmotic pressure, swell to destabilize the 
endosome membrane, and release the cargo into the cytosol, thus greatly enhancing the 
delivery efficiency. 
 
 
 
 
Fig. 2.3. The hypothesized release process of cargos that are entrapped in liposome-
coated calcium phosphate nano-precipitates in endosomes [17]. 
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Under physiological conditions, the extracellular Ca2+ concentration is ~1.2 mM 
whereas the cytosolic concentration is ~0.1 μM.  Low to moderate elevation of the Ca2+ 
concentration (0.2~0.4 μM) in the cytosol triggers apoptosis and higher cytosolic 
concentrations of Ca2+ (>1 μM) are associated with necrosis [18].  Therefore, it is 
beneficial to use magnesium phosphate precipitates (MgP) as the core of the proposed 
formulation instead of calcium phosphate to achieve lower cytotoxicity. 
2.1.3 Cargo Protein Cytochrome C (CytC) 
Cytochrome c (CytC) is a small hemeprotein found loosely associated with the 
inner membrane of mitochondria, and is a member of the family of cytochromes.  Unlike 
other cytochromes, CytC is highly water-soluble.  It is an essential component of the 
electron transport chain (ETC) with isoelectric point (pI) values in the range of 10.0-10.5, 
therefore carrying excessive positive charges at pH 7.4.  
Interestingly, it has long been known that isolated mitochondria can reversibly 
release and take up CytC, while the latter restores mitochondrial function [19].  Piel et al. 
reported an interesting and medically important example for the reversibility of CytC 
release, where intravenously injected CytC was taken into the cardiomyocytes and 
significantly improved the mitochondrial function in an animal model of sepsis.  The 
survival rate increased from 15% for the controls to about 50% in the septic mice that 
received the CytC injections [20], [21]. 
CytC is also known as a mediator of apoptosis through the intrinsic apoptosis 
pathway.  CytC is released from mitochondria into the cytosol due to formation of 
mitochondrial outer membrane permeabilization pore (MOMPP) when cells are stressed, 
and binds with apoptotic protease-activating factor 1 (Apaf-1).  The binding in turn 
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induced the binding between the CytC/Apaf-1 complex and dATP, which is necessary for 
oligomerization and formation of the apoptosome.  The apoptosome then recruits 
multiple procaspase-9 molecules and promotes their cleavage and activation into what are 
known as initiators of apoptosis.  Caspase-9 bound to the apoptosome acts as the 
cleavage factor of caspase-3, which is considered as the major enzyme that initiates the 
degradation of numerous cellular proteins to complete the apoptosis process [22]. 
Although CytC release is an essential step in the apoptotic cascade but that CytC 
release is not sufficient to induce death in all cells.  CytC-induced apoptosis is dependent 
on the concentration of cytosolic CytC, in that the release of endogenous CytC occurs 
proportionally to the extent of cellular ‘stress’ and that a certain threshold of released 
CytC must be reached before a cell commits to apoptosis [23]. 
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Fig. 2.4. Apoptosis pathways that involve cytochrome c (CytC) [22]. 
 
 
 
Free CytC also functions as a radical scavenger within the inner-membrane space.  
The oxidized form of CytC neutralizes superoxide, while both reduced and oxidized 
states of CytC deactivate hydrogen peroxide.  Since CytC constantly undergoes 
oxidation/reduction cycles in a respiring cell, both detoxification reactions can take place 
in the mitochondria by cytochrome c as a strong antioxidant [22]. 
2.2 Proposed Mechanism of Protein Delivery by the Proposed CytC LP/MgP 
At pH 7.4, the delivery system is expected to protect the cargo protein and to 
interact with the target cells either by ionic interactions.  After endocytosis, the elevated 
35 
 
concentration of protons inside the endosome will dissolve the MgP nano-core, which 
will then absorb water, expand in volume, and destabilize the endosomal membrane to 
release the cargo protein into cytosol.  
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Chapter 3: Preparation and Physiochemical Characterization of Magnesium 
Phosphate Nanoparticles with Cationic Lipid coating for Intracellular Delivery of 
Cytochrome C (CytC LP/MgP) 
3.1 Materials 
Magnesium chloride (Acros Organics), trisodium phosphate (Mallinckrodt 
Chemical), cyclohexane (EMD Millipore), Triton-X100 (EMD Millipore), 1-hexanol 
(Alfa Aesar), sodium citrate (J. T. Baker Chemical), absolute ethanol (Fisher Scientific), 
sulfuric acid (Acros), hydrogen peroxide 35% (Sigma-Aldrich), silica gel (Alfa Aesar), 
ammonium molybdate tetrahydrate (Sigma-Aldrich), Ascorbic acid (Acros Organics), 
phosphorous standard (Ricca Chemical), cytochrome c (MP Biomedicals), 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP) (Avanti Polar Lipids), cholesterol (Sigma-
Aldrich), and HEPES (Fisher Scientific) were used as purchased without further 
purification. 
3.2 Methods 
3.2.1 Preparation and Characterization of Cytochrome C-encapsulated Cationic 
Liposomes (CytC LP) 
Preparation of cytochrome c-encapsulated liposomes.  Cytochrome c powder 
with different weight was dissolved in 1 ml pH 7.4, 5 mM HEPES buffer to obtain 
cytochrome c solution with different concentration.  Aliquots of 156.48 µL 35.79 mM
 DOTAP and 74.24 µL 32.33 mM cholesterol solutions in chloroform, which were in the 
7:3 molar ratio to yield a mixture of 8 µmol total lipids, were added into a Pyrex glass 
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tube, and then evaporated by a rotary evaporator at room temperature for 15 minutes to 
form a lipid film.  The lipid film was placed under high vacuum for at least 4 hours to 
remove the residual solvent.  The dried lipid film was hydrated with 0.7 mL cytochrome 
c solution and mildly vortexed for 20 seconds at room temperature to obtain a suspension 
of cytochrome c-encapsulated liposomes.  The suspension was extruded 13 times through 
100 nm polycarbonate membrane (Nucleopore, Pleasanton, CA) by a Mini-Extruder 
(Avanti Polar Lipids, Alabaster, AL) at room temperature to yield cytochrome c-
encapsulated liposomes of smaller and more homogenous size. 
 
 
 
 
Fig. 3.1. Preparation of cytochrome c-encapsulated cationic liposomes. 
 
 
 
Size and ζ-potential measurements of cytochrome c-encapsulated liposomes.  
A 50-μL suspension of cytochrome c-encapsulated liposomes (CytC LP) was carefully 
added into a 10-mm square polystyrene cuvette (SARSTEDT, Germany) without creating 
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any air bubble.  The cuvette was closed with a lid, slightly agitated and placed into a 
Malvern Zetasizer for size measurements.  The temperature was maintained at 25 ℃.  
After size measurements, the suspension in the cuvette was diluted into 1 mL pH 
7.4, 5 mM HEPES buffer and the ζ-potential was measured immediately.  The diluted 
suspension was slowly infused into a folded capillary cell (Malvern Instruments, UK) 
without creating any air bubble.  The volume of the diluted suspension was adequate to 
completely cover the electrodes of the cell.  The two openings of the cell were closed 
with two lids and the cell was placed into the Malvern Zetasizer. The sample was 
equilibrated to 25 ℃ before measurements. 
All the samples were measured in triplicates and the data were reported as mean ± 
standard deviation of the triplicate measurements. 
TEM imaging.  The TEM was performed at the Electron Imaging Facility, 
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei 
Guo.  Briefly, a 5-µL the suspension of cytochrome c-encapsulated liposomes (CytC LP) 
was dropped onto a Pure Carbon Film Copper TEM grid on 400 mesh (TED PELLA 
INC., Redding, California).  The suspension on the gird was air-dried for about 1 minute 
and the excess fluid was blotted away with filter paper.  A few drops of uranyl acetate 
were then applied to the grid to generate a thin film of the suspension on the TEM grid, 
which was then immediately transferred onto a JEOL-1230 microscope for imaging at an 
accelerating voltage of 100 kV.  The digital images were recorded and analyzed with 
EMMENU4 (TIETZ imaging software). 
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3.2.2 Preparation and Characterization of Magnesium Phosphate Nanoparticles 
(MgP) 
Preparation of MgP nanoparticles.  Magnesium phosphate nanoparticle (MgP) 
was prepared by micro-emulsion precipitation.  A 15-mL mixture of organic solvents 
consisting of 75% cyclohexane, 15% Triton-X100 and 10% hexanol was added each into 
two round bottom flasks and stirred for 15 minutes.  An aliquot (300 µl) of 333.33 mM 
MgCl2 aqueous solution was added into one flask and another 300 µl 500 mM Na3PO4 
aqueous solution into the other flask. The two mixtures were each stirred continuously for 
30 minutes to form reverse water-in-oil (w/o) microemulsions.  The Na3PO4 
microemulsion was promptly added into the MgCl2 microemulsion followed by another 
30 minutes of continuous stirring to generate MgP nanoparticles.  Sodium citrate (250 
µL, 15 mM aqueous solution) was then added dropwise into the microemulsion to endow 
the MgP nanoparticles with negative surface charges.  The mixture was then stirred for 
another 15 minutes until the microemulsion turned translucent.  
For the separation of the MgP nanoparticles, 4 g silica gel (60-200 mesh) was 
suspended in 30 mL ethanol.  The afore prepared microemulsion containing the MgP 
nanoparticle was poured into the silica gel-ethanol mixture with continuous stirring for 15 
minutes to break the microemulsion and to adsorb the magnesium phosphate (MgP) 
nanoparticles onto the silica gel.  Organic solvents were washed away with 200 mL 
ethanol and magnesium phosphate nanoparticles were then sequentially eluted with 15 
mL 75% ethanol, 15 mL 50% ethanol, and two 15 mL 25% ethanol in water.  The eluted 
nanoparticles were collected in eight 7.5 mL fractions.  Suspensions of MgP 
nanoparticles in water were obtained after removing ethanol by rotary evaporation.  The 
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entire process was carried out at 4ºC temperature, and the MgP nanoparticles were 
quantified using the phosphorous assay as detailed in the following section. 
 
 
 
 
 
Fig. 3.2. Preparation of MgP nanoparticles. 
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Phosphorus assay.  10 N H2SO4 was prepared by carefully adding 1 mL stock 35 
N H2SO4 to 2.5 mL deionized water.  10% H2O2 was prepared by mixing 1 mL stock 
35% H2O2 with 2.5 mL deionized water.  Molybdate reagent was prepared by dissolving 
0.22 g ammonium molybdate tetrahydrate in 2.5 mL of 10 N H2SO4, followed by dilution 
with deionized water to 100 mL.  10% ascorbic acid solution was obtained by dissolving 
5 g ascorbic acid in 50 g deionized water.  
For the preparation of standards, 6 different volumes of a phosphorus standard 
solution were placed into 6 different clean Pyrex tubes as follows: 0 nmol (0 µL) as 
blank, 125 nmol (77.5 µL), 250 nmol (155 µL), 375 nmol (232.5 µL), 500 nmol (310 
µL), and 625 nmol (387.5 µL).  
For each sample, 20 µL of a suspension of MgP nanoparticle was placed into the 
bottom of a Pyrex tube.  An aliquot (0.4 mL) of 10 N H2SO4 was added to each sample 
and standard.  All tubes were then heated in a solid anodized aluminum block in the fume 
hood at 200-210 ℃ for 60 minutes. The tubes were removed from the block and allowed 
to cool for 10 minutes at room temperature.  An aliquot (0.1 mL) of 10% H2O2 was added 
to each tube.  All tubes were heated again at 190-210 ℃ for 10 minutes and then cooled 
at room temperature for 10 minutes.  The molybdate reagent (4.7 mL) and 10% ascorbic 
acid (0.5 ml) were added to each tube and all tubes were vortexed immediately for 10 
seconds.  All tubes were then heated at 100 ℃ for 10 minutes, when blue color was 
observed in tubes containing substantial phosphate. The tubes were then cooled on the ice 
to reach room temperature rapidly.  The UV absorbance at 800 nm was then determined 
by UV-visible spectrophotometer, UV-1601 (Shimadzu, Japan) after the standard tube 
containing 0 nmol phosphate used to manually adjust the absorbance to zero.  A 
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calibration curve was generated using the absorbance of standard samples and used to 
determine the amount of phosphorus in unknown samples. 
Size and ζ-potential measurements of MgP nanoparticles.  An aliquot (50 μL) 
of a suspension of MgP nanoparticles was carefully added into a 10-mm square 
polystyrene cuvette (SARSTEDT, Germany) without creating any air bubble.  The 
cuvette was closed with a lid, slightly agitated and placed into the Malvern Zetasizer.  
The temperature was maintained at 25 ℃.  
After size measurements, the suspension in the cuvette was diluted to 1 mL using 
deionized water and the ζ-potential was measured immediately.  The diluted suspension 
was slowly infused into a folded capillary cell (Malvern Instruments, UK) without 
creating any air bubble.  The volume of the diluted suspension was adequate to 
completely cover the electrodes of the cell.  The two openings of the cell were closed 
with two lids and was placed into the Zetasizer. The sample was equilibrated to 25 ℃ 
before measurements. 
All the measurements were in triplicate and the data were reported as mean ± 
standard deviation of the triplicates. 
TEM imaging.  The TEM was performed at the Electron Imaging Facility, 
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei 
Guo.  Briefly, a 5-µL the suspension of magnesium phosphate nanoparticles (MgP) was 
dropped onto a Pure Carbon Film Copper TEM grid on 400 mesh (TED PELLA INC., 
Redding, California).  The suspension on the gird was air-dried for about 1 minute and 
the excess fluid was blotted away with filter paper.  The thin film of the suspension on 
the TEM grid was then immediately transferred onto a JEOL-1230 microscope for 
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imaging at an accelerating voltage of 100 kV.  The digital images were recorded and 
analyzed with EMMENU4 (TIETZ imaging software). 
3.2.3 Wrapping of Magnesium Phosphate Nanoparticles with Cytochrome C-
encapsulated Cationic Liposomes (CytC LP/MgP) 
Preparation of MgP nanoparticles coated with cytochrome c-encapsulated 
liposomes.  The phosphoric concentration of MgP nanoparticles was determined by the 
previous phosphorus assay so that the amount of MgP nanoparticles to be mixed with 
CytC LP matched a 7:3 molar ratio between the amount of total lipids in CytC LP and the 
amount of phosphorus in MgP nanoparticles.  The amount of MgP nanoparticles to be 
added to the CytC LP was determined based on the phosphorus assay, and the 
corresponding volume of the suspension of MgP nannoparticles was mixed with CytC LP 
for 1 hour at room temperature.  Appropriate volume of pH 7.4, 5 mM HEPES buffer was 
used to dilute CytC solution to reach an appropriate concentration. 
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Fig. 3.3. Spontaneous wrapping of negatively charged MgP nanoparticles by cationic 
liposomes. 
 
 
 
Size and ζ-potential measurements of cytochrome c-encapsulated liposomes 
with MgP nanoparticles.  An aliquot (50 μL) of a suspension of cytochrome c-
encapsulated liposomes with MgP nanoparticles (CytC LP/MgP) was carefully added into 
a 10-mm square polystyrene cuvette (SARSTEDT, Germany) without creating any air 
bubble.  The cuvette was closed with a lid, slightly agitated and placed into the Malvern 
Zetasizer.  The temperature was maintained at 25 ℃.  
After size measurements, the suspension in the cuvette was diluted to 1 mL using 
deionized water and the ζ-potential was measured immediately.  The diluted suspension 
was slowly infused into a folded capillary cell (Malvern Instruments, UK) without 
creating any air bubble.  The volume of the diluted suspension was adequate to 
completely cover the electrodes of the cell.  The two openings of the cell were closed 
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with two lids and was placed into the Zetasizer. The sample was equilibrated to 25 ℃ 
before measurements. 
All the measurements were in triplicate and the data were reported as mean ± 
standard deviation of the triplicates. 
TEM imaging.  The TEM was performed at the Electron Imaging Facility, 
Department of Molecular and Cellular Biology, UC Davis with the help from Dr. Fei 
Guo.  Briefly, a 5-µL the suspension of cytochrome c-encapsulated liposomes with MgP 
nanoparticles (CytC LP/MgP) was dropped onto a Pure Carbon Film Copper TEM grid 
on 400 mesh (TED PELLA INC., Redding, California).  The suspension on the gird was 
air-dried for about 1 minute and the excess fluid was blotted away with filter paper.  A 
few drops of uranyl acetate were then applied to the grid to generate a thin film of the 
suspension on the TEM grid, which was then immediately transferred onto a JEOL-1230 
microscope for imaging at an accelerating voltage of 100 kV.  The digital images were 
recorded and analyzed with EMMENU4 (TIETZ imaging software). 
3.3 Results 
3.3.1 Phosphorus Assay 
The phosphate in the proposed formulation is important for buffering the protons, 
and thus for preventing the acid-induced protein denaturation. The phosphate also 
contributes to the high osmotic pressure from the dissolved MgP.  The MgP nanoparticles 
are quantified using the phosphorus assay.  The concentration of phosphate ions in a 
fraction of nanoparticle is quantified based on a colorimetric method.   
In the gradient elution of MgP nanoparticles, the concentration of phosphates in 
the eluant fractions depended on the percentage of water in the eluting solvent.  The 
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result (Fig. 3.4.) shows that the concentration of phosphates in the second fraction that 
was eluted with 25% ethanol in water was the highest at 24.53±3.22 nmol/mL.  It is 
advisable to perform this assay every time in order to quantify phosphates present in the 
sample. 
 
 
 
 
Fig. 3.4. Concentration of phosphate in fractions eluted with 25% of ethanol collected 
from chromatograph. 
 
 
 
The eluted MgP nanoparticles were collected in eight 7.5 mL fractions.  Two 
fractions each were collected after elution with 75% and 50% ethanol.  Four fractions 
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were collected after elution with 25% ethanol.  Majority of phosphate concentrated in the 
second fraction of the eluent generated with 25% ethanol. 
The initial preparation of MgP nanoparticles used 500 mM MgCl2 and 500 mM 
(NH4)2HPO4 aqueous solutions.  The resultant mixed precipitates of dibasic magnesium 
phosphate trihydrate (newberyite, MgHPO4∙3(H2O)) and cattiite (Mg3(PO4)2∙22H2O) at 
pH 7.4, 4 ℃ [24], and a Mg2+:PO43- ratio of 1:1 showed relatively low phosphorous 
concentration of 7.79±0.93 nmol/mL in the second fraction that was eluted with 25% 
ethanol (Fig. 3.5.). 
Alternatively, 333.33 mM MgCl2 and 500 mM Na2HPO4 aqueous solutions were 
mixed in a physiological molar ratio of Mg2+:PO4
3- = 2:3.  Although the same mixed 
precipitates were produced [24], the resultant MgP nanoparticles showed a relatively high 
phosphate concentration of 19.88±2.93 nmol/mL in the second fraction that was eluted 
with 25% ethanol (Fig. 3.5.).  
As another alternative, 333.33 mM MgCl2 and 500 mM Na3PO4 aqueous 
solutions were mixed in a physiological molar ratio of Mg2+:PO4
3- of 2:3, which only 
formed cattiite (Mg3(PO4)2∙22H2O) precipitates at pH 7.4, 4 ℃ [24].  Surprisingly, the 
resultant MgP nanoparticles showed a phosphate concentration of 24.53±3.22 nmol/mL 
in the second fraction that was eluted with 25% ethanol (Fig. 3.5.), which is a much 
higher phosphate concentration than the previous two conditions of making MgP 
nanoparticles. 
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Fig. 3.5. Na3PO4 improved the phosphorous concentration in magnesium phosphate 
nanoparticles (MgP). 
 
 
 
3.3.2 Colloidal Properties of MgP, CytC LP and CytC LP/MgP 
The result of size and surface charge measured by dynamic light scattering (DLS) 
(Table 3.1.) shows that the average diameter of both CytC LP and CytC LP/MgP were 
around 150 nm.  Surprisingly, the size distribution by volume of MgP showed two peaks, 
which will be discussed later.  The ζ-potential changed with compositions of the colloid, 
from -9.58 mV of negatively charged MgP, to 48.1 mV of CytC LP due to the cationic 
lipids, and then to 27.2 mV of the final formulation of CytC LP/MgP that was made of 
both MgP and CytC LP. 
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Table 3.1. Size and ζ -potential of MgP, CytC LP and CytC LP/MgP. 
  Size (nm) PDI ζ-Potential (mV) 
CytC LP 124.6±38.70 0.058 48.1±9.80 
MgP 
61.08±9.915 
380.7±96.47 
(two peaks) 
0.362 -9.58±4.13 
CytC LP/MgP 158.0±64.17 0.099 27.2±7.30 
Each value represents the mean±S.D. of at least three experiments. 
 
 
 
3.3.3 TEM Imaging of MgP, CytC LP and CytC LP/MgP 
Fig. 3.6. (A) shows that most MgP nanoparticles in TEM images matched the first 
peak in the size distribution of MgP as measured by DLS. This phenomenon will be 
discussed later.  The other finding is that although the electrostatic repulsion brought by 
sodium citrate kept nanoparticles separated, some MgP still stuck together. 
Fig. 3.6. (B) shows that the cargo protein cytochrome c was encapsulated into 
CytC LP. 
Fig. 3.6. (C) is the TEM image of CytC LP/MgP.  MgP nanoparticles were in the 
center of liposomes as expected. 
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 (with negative staining)    (without negative staining) 
 
Fig. 3.6. TEM images of (A) MgP, (B) CytC LP, and (C) CytC LP/MgP. 
 
 
 
3.4 Discussion 
3.4.1 MgP Produced by the Strategy of Microfluidic Mixing 
The NanoAssemblr Benchtop (Precision Nanosystems, Vancouver, BC) is a 
nanoparticle synthesis system, whose proprietary microfluidics technology enables 
controlled, bottom-up, molecular self-assembly of nanoparticles through millisecond 
mixing of components at nanoliter scale.  This technique is time-saving and allows large-
scale preparation of MgP nanoparticles within one day.  However, the best result (Fig. 
3.6.) of MgP preparation with a size of 79.61±25.82 nm in diameter and a ζ-potential of -
8.00±7.28 mV was not reproducible.  Consequently, the micro-emulsion method was 
eventually elected over this alternative method. 
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Fig. 3.7. The most optimized size of MgP generated by the NanoAssemblr Benchtop. 
 
 
 
3.4.2 Comparison of DLS and TEM Characterizations of CytC LP/MgP 
Dynamic light scattering (DLS) measures the size and surface zeta potential of 
small particles.  Brownian motion of water molecules moves small, suspended particles 
in and out of the detection of their scattered light to cause fluctuation of the scattered 
light intensity.  The fluctuation can then be used to calculate the hydrodynamic diameter 
of the particles.  DLS is convenient and can detect a large population of the particles in 
the suspension.  However, DLS cannot measure the size of the particle core, the size of 
varied surface structures, and is limited by the particle concentration. 
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Transmission electron microscope (TEM) can be used to examine details of the 
structure of a formulation, such as aggregations and cores with a simple sample 
preparation.  TEM is not easily accessible in common labs and quantitation of the size of 
particles need to sample an enormous number of images, which is time-consuming and 
inconvenient. 
As shown in Fig. 3.8., two peaks were observed in the DLS analysis of the size of 
MgP nanoparticles.  The first peak showed the hydrodynamic diameter of 61.08±9.915 
nm, which possessed 56.2% by volume, indicating this is the diameter that reflect the size 
of most of the MgP nanoparticles.  The second peak showed the size of 380.7±96.47 nm, 
which possessed 43.8% by volume, suggesting that MgP might undergo aggregation. 
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Fig. 3.8. Size distribution by volume of MgP measured by DLS. 
 
 
 
As shown in Fig. 3.6. (A), the aggregation of MgP nanoparticles were directly 
observed by TEM.  Despite the addition of sodium citrate, the ζ-potential of MgP was 
only slightly negative around -10 mV whereas a surface charge of either higher than +30 
mV or lower than -30 mV is needed keep the particles stable in a suspension.  Because of 
this, the particles of MgP could not sufficiently repulse one another by electrostatic force 
to prevent aggregation. 
DLS studies showed two peaks of 380.7±96.47 nm and 61.08±9.915 nm in 
hydrodynamic diameter for MgP, one peak of 124.6±38.70 nm for CytC LP, and one 
peak of 158.0±64.17 nm for the final formulation of CytC LP/MgP.  From TEM image 
(Fig. 3.6. (C)), the size of the final formulation of CytC LP/MgP was around 100 nm, 
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which was still in the range of size distribution by volume of DLS.  There were two 
possible reasons to explain why the size of final CytC LP/MgP (Fig. 3.9.) was not close 
to the predominant size of MgP around 61.08 nm: 1) from Fig. 3.6. (C), liposomes 
engulfed more than one MgP nanoparticles in the core to give to a larger size of final 
CytC LP/MgP; 2) lipid membranes loosely wrapped around the MgP nano-core, to form a 
relatively thick liposomal shell.  Further TEM investigation is needed to confirm these 
speculations. 
From TEM image (Fig. 3.6. (C)), CytC LP/MgP carrying a magnesium phosphate 
nano-core, a coating of lipid membranes encapsulated with cargo protein CytC was 
successfully prepared.  There was a mechanism how the interaction happened between 
inorganic nanoparticles and lipid membranes: engulfment of negatively charged MgP 
with cationic CytC LP, which can be reflected on the change of ζ-potential.  When the 
engulfment happened, the -potential changed from 48.1 mV on CytC LP to 27.2 mV on 
the final formulation of CytC LP/MgP, which can be explained by the disproportional 
distribution of positive charges to the inside of CytC LP/MgP due to the electrostatic 
interaction between a large amount of positive charges on lipid membranes and 
negatively charged MgP, leading to the decrement of the density of positive charges 
outside of CytC LP/MgP. 
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Fig. 3.9. Volume distribution of the size of CytC LP/MgP per DLS. 
 
 
 
3.5 Conclusion 
CytC LP/MgP was successfully prepared and its physicochemical properties were 
characterized.  CytC LP/MgP had the approximate size of 150 nm in diameter and the 
surface charge around 30 mV.
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Chapter 4: Characterization of Cationic Liposome-coated Magnesium Phosphate 
Nanoparticles for Intracellular Delivery of Cytochrome C (CytC LP/MgP) into 
Lung Cancer Cells A549 
4.1 Introduction 
A549, a lung adenocarcinoma cell line belongs to non-small cell lung cancer 
(NSCLC), which accounts for 40% of all lung cancers.  Adenocarcinoma occurs mainly 
in current and former smokers, but is also the most common type of lung cancer seen in 
non-smokers.  Adenocarcinoma is more common in women than in men and is more 
likely to occur in young people than other types of lung cancer [25].  Cytochrome c 
(CytC) is a potential anticancer protein that may induce apoptosis by the mitochondrial 
pathway.  Cellular uptake of CytC in different formulations was monitored by green-
fluorescent dye Alexa Fluor® 488 that can be conjugated to the protein.  The MTS Assay 
on cell viability was conducted to study the cell killing effect of CytC LP/MgP in A549 
cells. 
4.2 Materials 
A549 cells were purchased from ATCC, cytochrome c (MP Biomedicals), 
DMEM/F-12, 50/50, 1X (Corning), fetal bovine serum (Gemini), penicillin-streptomycin 
solution (Cellgro), L-glutamine(Cellgro), trypsin 0.25% (1X) (HyClone), Alexa FluorTM 
488 carboxylic acid, succinimidyl ester (Thermo Fisher Scientific), DMSO (Fisher
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 Scientific), PBS with 1 M NaCl solution (Santa Cruz Biotechnology), MitoRed 
(PromoKine), PBS, 1X (Corning), 4% paraformaldehyde in phosphate-buffered saline 
(Boston BioProducts), Hoechst 33342 (Thermo Scientific), RPMI medium 1640 (1X) 
(Gibco), CellTiter96® AQueous One solution cell proliferation assay (Promega) were 
purchased and used without further purification. 
4.3 Methods 
4.3.1 Fluorescence Imaging Analysis 
The preparations of formulations.  Conjugation of Alexa Fluor® 488 to 
cytochrome c (Alexa 488-labeled CytC).  10 mg of cytochrome c was dissolved in 1 mL 
of pH 8.3, 5 mM HEPES buffer.  Alexa Fluor™ 488 NHS Ester (Succinimidyl Ester) was 
dissolved in DMSO at 10 mg/mL.  While stirring or vortexing the cytochrome c solution, 
75 μL of the reactive dye solution was slowly added.  The reaction mixture was incubated 
for 1 hour at room temperature with continuous stirring.  The conjugate was separated 
from unreacted labeling reagent using Amicon® Ultra 15 mL centrifugal filter (EMD 
Millipore, Billerica, MA) with 3 kDa molecular weight cutoff according to the following.  
The mixture of cytochrome c and dye was diluted to 4 mL with pH 7.4, 5 mM HEPES 
buffer.  The diluted mixture was centrifuged at 4000 x g at 25 °C for 1 hour.  The 
concentrate in the filter device sample reservoir was diluted to 4 mL again and then 
centrifuged for another 1 hour.  The concentrate was diluted back to 2 mL to yield 245.14 
µM Alexa Fluor® 488-labeled cytochrome c (Alexa 488-labeled CytC) solution.  HEPES 
buffer (0.2 mL, 5 mM at pH 7.4) was added to dilute the resultant suspension of Alexa 
488-labeled CytC to 146.95 µM. 
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Preparation of LP/MgP containing Alexa Fluor® 488-labeled cytochrome c 
(Alexa 488-labeled CytC LP/MgP).  DOTAP (156.48 µL 35.79 mM) and cholesterol 
(74.24 µL 32.33 mM) solutions in chloroform were added into a Pyrex glass tube to yield 
a mixture of 8 µmol total lipids in 7:3 molar ratio. The organic solvent of the mixture was 
evaporated by a rotary evaporator at room temperature for 15 minutes to form a lipid 
film, which was placed under high vacuum condition for at least 4 hours to remove the 
residual solvent.  The dried lipid film was hydrated with 0.7 mL of 245.14 µM Alexa 
Fluor® 488-labeled cytochrome c solution and mildly vortexed for 20 seconds at room 
temperature to obtain a suspension of liposomes containing Alexa Fluor® 488-labeled 
cytochrome c (Alexa 488-labeled CytC LP).  The suspension was extruded 13 time 
through 100 nm polycarbonate membrane (Nucleopore, Pleasanton, CA) by a Mini-
Extruder (Avanti Polar Lipids, Alabaster, AL) at room temperature.  Based on the 
phosphorus assay, 138.46 µL of MgP nanoparticles, which carried the phosphoric 
concentration of 10.61 mM, was mixed with 0.3 mL of Alexa 488-labeled CytC LP, 
followed by incubation for 1 hour at room temperature.  Size and ζ-potential of Alexa 
488-labeled CytC LP with MgP nanoparticles (Alexa 488-labeled CytC LP/MgP) were 
measured by the Zetasizer, when 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to 
obtain 146.95 µM Alexa Fluor® 488-labeled CytC, 6.85 mM total lipids, and 2.94 mM 
phosphate from MgP in the final formulation. 
Preparation of Alexa Fluor® 488-labeled cytochrome c-complexed with MgP 
nanoparticles (Alexa 488-labeled CytC+MgP).  Based on the phosphorus assay, 138.46 
µL of MgP nanoparticles, which carry the phosphoric concentration was 10.61 mM, was 
mixed with 0.3 mL of Alexa 488-labeled CytC, followed by incubation for 1 hour at 
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room temperature.  Size and ζ-potential of Alexa Fluor® 488-labeled cytochrome c-
complexed with MgP nanoparticles (Alexa 488-labeled CytC+MgP) were measured by 
the Zetasizer, for which 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to obtain 
146.95 µM Alexa Fluor® 488-labeled CytC and 2.94 mM phosphate from MgP in the 
final formulation. 
Preparation of bare cationic liposomes (bare LP).  DOTAP (156.48 µL 35.79 
mM) and cholesterol (74.24 µL 32.33 mM) solutions in chloroform were added into a 
Pyrex glass tube to yield a mixture of 8 µmol total lipids in 7:3 molar ratio. The organic 
solvent of the mixture was evaporated by a rotary evaporator at room temperature for 15 
minutes to form a lipid film, which was placed under high vacuum condition for at least 4 
hours to remove the residual solvent.  The dried lipid film was hydrated with 0.7 mL of 
pH 7.4, 5 mM HEPES buffer solution and mildly vortexed for 20 seconds at room 
temperature to obtain a suspension of bare cationic liposomes (bare LP).  The suspension 
was extruded 13 time through 100 nm polycarbonate membrane (Nucleopore, Pleasanton, 
CA) by a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL) at room temperature.  Size 
and ζ-potential of bare LP were measured by the Zetasizer.  HEPES buffer (0.2 mL, 5 
mM at pH 7.4) was added to dilute the resultant suspension of bare LP to 6.85 mM. 
Preparation of bare cationic liposomes with MgP nanoparticles (bare LP/MgP).  
Based on the phosphorus assay, 138.46 µL of MgP nanoparticles, which carry the 
phosphoric concentration of 10.61 mM, was mixed with 0.3 mL of cationic, followed by 
incubation for 1 hour at room temperature.  Size and ζ-potential of bare cationic 
liposomes with MgP nanoparticles (bare LP/MgP) were measured by the Zetasizer, for 
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which 61.54 µL of pH 7.4, 5 mM HEPES buffer was added to obtain the final 
formulation. 
The preparation of stock solution of MitoRed for mitochondrial staining.  To 
prepare a 200 µM stock solution, 50 µg vial of MitoRed powder was dissolved in 460 µL 
anhydrous DMSO. 
The preparation of Hoechst 33342 working solution for nuclear staining.  A 
dilution of Hoechst 33342 was prepared in PBS for a final concentration of 1 mg/mL.  
The resultant solution was diluted to 1 μg/mL in PBS for nuclear staining. 
The preparation of cell culture and staining.   The A549 cells were grown in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 1:1 (DMEM/F-12, 1:1) 
medium, supplemented with 10% fetal bovine serum (FBS), 1% antibiotics (penicillin 
5000 U/mL, and streptomycin 5000 μg/mL) and 1% L-glutamine.  A549 cells were 
seeded in two 6-well plates (Ultra CruzTM, Santa Cruz Biotechnology) at a density of 2 x 
105 cells/well and incubated under the condition of 5% CO2 at 37 ℃ overnight (12 hours) 
to obtain 50% - 80% confluence. 
The wells with or without cells were treated with 2 mL of different formulations 
pre-diluted with culture medium to obtain 14.69 µM Alexa Fluor® 488-labeled CytC, 
0.685 mM lipids, or 0.294 mM MgP in formulations.  After incubation at 37 ℃ for three 
hours, cells were washed once with PBS with 1 M NaCl solution for several seconds. 
For the staining of mitochondria, MitoRed was diluted to 200 nM in pre-warmed 
culture medium.  PBS in cell wells was removed and 1 mL of the diluted MitoRed 
solution was added into each well.  Cells were incubated for 30 minutes at 37 ℃.  The 
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MitoRed solution was removed and cells were washed with culture medium once and 
PBS once, each time for 3 minutes with the benchtop orbital shaker. 
For fixation, cells were first washed with PBS.  PBS was then removed followed 
by addition of pre-warmed 4% paraformaldehyde (PFA) solution in PBS.  Cells were 
incubated for 17 minutes, and then washed with PBS twice for 3 minutes each time with 
a benchtop orbital shaker. 
For the staining of nuclei, cells were washed with PBS. After removing PBS, 1 
mL of 1 μg/mL Hoechst 33342 solution was added to completely cover the cells in each 
well.  Aluminum foil was placed over the sample to protect it from light.  Cells were 
incubated at room temperature for 5 minutes and washed twice with PBS for 3 minutes 
each time with the benchtop orbital shaker. 
Fluorescence imaging assay.  Fluorescent images were acquired with a 
fluorescence microscope BZ-X710 (KEYENCE, Japan).  Exact same parameters 
(excitation light: 40%; objective lens: 4x; exposure time for BZ-X filter DAPI: 1/1.2 
seconds; exposure time for BZ-X filter GFP: 3 seconds; exposure time for BZ-X filter 
TxRed: 3s) were set for imaging all 6 different treatments (Alexa 488-labeled CytC, 
Alexa 488-labeled CytC/MgP, bare LP/MgP, bare LP, Alexa 488-labeled CytC+MgP, 
and no treatment) and their control groups with no cells. 
Images under different filters were taken from each well and digitally 
superimposed.  The green fluorescence of the image _CH1 was from Alexa 488 labeled-
CytC in A549 cells, the red fluorescence of the image _CH2 was from mitochondria in 
A549 cells, and the blue fluorescence of the image _CH3 was from nuclei in A549 cells.  
63 
 
Each fluorescence intensity was measured using ImageJ from National Institutes of 
Health (NIH) under the same thresholds. 
4.3.2 Cell Viability Assay 
A549 cells were grown in RPMI-1640 medium supplemented with 10% fetal 
bovine serum (FBS), 1% antibiotics (penicillin 5000 U/mL, and streptomycin 5000 
μg/mL) and 1% L-glutamine. 
A549 cells were seeded in 96-well plates (Ultra CruzTM, Santa Cruz 
Biotechnology) at a density of 5000 cells/well and incubated under 5% CO2 at 37 ℃ 
overnight (12 hours) to obtain around 50% to 80% confluence.  Cells were treated with 
100 µL of 6 different formulations (Free CytC, CytC LP/MgP, bare LP, bare LP/MgP, 
MgP, and CytC+MgP).  The formulations are prepared in the same way as those for the 
aforementioned fluorescence imaging assay, each applied at 8 different concentrations by 
pre-dilution with complete culture medium to carry 50, 10, 5, 1, 0.5, 0.1, 0.05 and 0.01 
µM CytC, 428.47, 85.69, 17.14, 8.57, 4.28, 0.86, 0.43 and 0.09 µM total lipids, or 180, 
36.7, 18.4, 3.67, 1.84, 0.367, 0.184, 0.0367 µM phosphate from MgP.  After 48-hour 
incubation at 37 ℃, cells were washed twice with PBS, each time for 3 minutes with the 
benchtop orbital shaker. 
Cell viability was measured by the MTS assay.  20 µL of CellTiter 96® AQueous 
One Solution Reagent was added into each well of the 96-well plate containing 100 µL 
culture medium without phenol red.  After 4 hours of incubation at 37 ℃, the absorbance 
of all the contents at 490 nm was measured by Biotek Synergy HT Multimode microplate 
reader (BioTek Instruments, Winooski, VT).  The absorbance of cells without any 
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treatment was taken as 100% viability, and the absorbance of wells containing medium 
but without cells was taken as background. 
Cell viability was calculated by the following formula: 
Cell Viability [%] =  
OD490 sample−OD490 background
OD490 control−OD490 background
 ×  100%,  where OD490 sample is the 
UV absorbance of cells treated with a formulation at an aforementioned concentration, 
OD490 control is the UV absorbance of cells treated with no formulation but growth 
media as a control for 100% viability, and OD490 background is the UV absorbance of 
wells with media but no cells. 
Dose-response curves for cell viability of A549 cells treated with different 
formulations were depicted, and the IC50 was calculated using GraphPad Prism (Version 
6.01). 
4.4 Results 
4.4.1 Fluorescence Imaging of A549 Cells after Exposure to Formulations for 3 h 
The A549 cells in 6-well plates were treated with formulations at 14.69 μM CytC, 
0.685 mM total lipids, and 0.294 mM phosphate from MgP for 3 hours and the results of 
the following florescent imaging are presented in Fig. 4 and Table 4.1. 
Cells treated with free Alexa 488-labeled CytC did not display significant green 
fluorescence (Fig. 4.1. (A) and Table 4.1.), indicating that Alexa 488-labeled CytC could 
not efficiently penetrate through cell membrane into the A549 cells.  Furthermore, CytC 
LP/MgP caused much more cargo protein CytC attached to A549 cells than any other 
formulations and the no-treatment group as indicated by the strongest green fluorescence 
of the corresponding cells (Fig. 4.1. (B) and Table 4.1.). 
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CytC LP/MgP and bare LP displayed less mitochondrial staining than other 
formulations and the no-treatment group, (Fig. 4.2. (B), (C), (D) and Table 4.1.).  In 
addition, CytC LP/MgP and bare LP displayed more nuclear staining than other 
formulations and the no-treatment group, (Fig. 4.3. (B), (C), (D) and Table 4.1.). 
 
 
 
 A      B 
 
 
 C      D 
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Fig. 4.1. The attachment of Alexa 488-labeled cytochrome c to A549 cells after 3 h 
incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP, 
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment 
group measured as shown by fluorescence microscopy. 
 
 
 
 A      B 
 
 
 C      D 
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Fig. 4.2. The uptake and intramitochondrial accumulation of MitoRed in A549 cells after 
3 h incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP, 
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment 
group measured as shown by fluorescence microscopy. 
 
 
 
 A      B 
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Fig. 4.3. The uptake and intranuclear accumulation of Hoechst 33342 in A549 cells after 
3 h incubation with (A)Alexa 488-labeled CytC, (B)Alexa 488-labeled CytC LP/MgP, 
(C)bare LP/MgP, (D)bare LP, (E)Alexa 488-labeled CytC+MgP, and (F)no-treatment 
group measured as shown by fluorescence microscopy. 
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Table 4.1. Semi-quantitation of fluorescence intensity for staining of CytC, nuclei and 
mitochondria in A549 cells. 
 CytC Nuclei Mitochondria 
CytC 1±1 2511±34 25847±178 
CytC LP/MgP 3616±42** 14305±114△△ 376±18## 
CytC+MgP 2±1 1564±23 43399±238 
Bare LP 1±1 5959±53△△ 5092±49## 
Bare LP/MgP 1±1 6188±41△△ 1440±27## 
No treatment 1±1 2868±36 41564±203 
Each value represents the mean±S.D. of at least three measurements.  Significant 
difference **P<0.01 vs. CytC of no treatment, △△P<0.01 vs. nuclei of no treatment, and 
##P<0.01 vs. mitochondria of no treatment (Student’s t-test). 
 
 
 
4.4.2 MTS Assay on A549 Cell Viability after Exposure to Formulations for 48 h 
The highest concentration of total lipids in wells of 96-well plates is 0.428 mM, 
and of phosphate from MgP is 0.184 mM.  Free CytC showed relatively high cytotoxicity 
at low concentrations.  At the same time, high cytotoxicity was observed in a 
concentration-dependent manner for bare LP with or without MgP.  However, lower 
cytotoxicity was found from CytC LP/MgP than from bare LP with or without MgP. 
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Fig. 4.4. MTS assay on cell viability after exposing A549 Cells to free CytC (blue), CytC 
LP/MgP (purple), bare LP/MgP (red), bare LP (green), CytC+MgP (dark green), and 
MgP (orange) for 48 h. 
 
 
 
Table 4.2. IC50 normalized by the concentration of CytC. 
 Free 
CytC 
Bare 
LP/MgP 
Bare LP 
CytC 
LP/MgP 
CytC LP MgP 
CytC+M
gP 
IC50 of 
CytC 
(µM) 
~ 0.231 1.23 1.179 10.59 14.98 ~ 9.21 ~ 243.1 
 
 
 
4.5 Discussion 
4.5.1 Fluorescence Imaging 
Sephadex® G-50 Fine gel filtration resin (GE Healthcare Life Sciences, 
Pittsburgh, PA) for the separation of molecules from 1,000 to 30,000 Dalton was used 
first to separate the conjugate from unreacted labeling reagent.  However, the CytC 
(labeled or unlabeled) was poorly resolved from unreacted Alexa 488 dye on a 25 cm 
column, as indicated by Fig. 4.5, suggesting that CytC and unreacted Alexa 488 dye were 
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collected as a mixture. The poor resolution may be partly due to the small molecular 
weight of CytC (12 kDa). 
 
 
 
 
Fig. 4.5. Column chromatography by Sephadex® G-50 Fine. 
 
 
 
Sephadex® G-25 Medium gel filtration resin (GE Healthcare Life Sciences, 
Pittsburgh, PA) with a separation range of 1000 to 5000 Dalton was then attempted to 
improve the resolution.  However, the CytC (labeled or unlabeled) was poorly resolved 
from unreacted Alexa 488 dye by a 25-cm column, as indicated by lack of two separate 
peaks of Alexa 488-labeled CytC and unreacted Alexa 488 dye by UV-Visible 
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Spectrometry readout at 488 nm (Fig. 4.6., the signal at 550 nm is from CytC), which 
meant CytC and unreacted Alexa 488 dye were collected simultaneous as a mixture. 
 
 
 
 
Fig. 4.6. UV-Visible Spectrometry readout for the separation of (yellow) CytC at 550 nm 
from (blue) Alexa 488 dye at 488 nm by Sephadex® G-25 Medium. 
 
 
 
Eventually, Amicon® Ultra 15 mL centrifugal filter (EMD Millipore, Billerica, 
MA) with 3 kDa molecular weight cutoff allowed the separation of cytochrome c from 
the unreacted dye molecules whose molecular weight is smaller than 3 kDa.  The protein-
dye mixture was centrifuged twice on Centrifuge 5810 R (Eppendorf, Germany) at 4000 
x g at 25 ℃ (1 h each time) to yield the labeled cytochrome c at a recovery rate of ~60%. 
Jones et al. reported that CytC contains cell penetrating peptide (CPP) epitopes in 
the N- and C-terminal helices.  Such CPPs can mediate the cellular uptake of free CytC 
protein [26].  The reason why Alexa 488-labeled CytC could not distribute into cells 
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might be that after NHS esters (or succinimidyl esters) of Alexa Fluor® 488 reacted with 
non-protonated aliphatic amine groups of proteins to form stable carboxamide bonds, the 
conjugated Alexa 488 moiety hindered the cell penetrating peptide (CPP) epitopes in the 
N-terminal helices of CytC. 
All formulations containing the cationic lipid DOTAP reduced the uptake and 
intramitochondrial accumulation of MitoRed, which is probably due to the change of 
mitochondria’s inner transmembrane potential (m) by DOTAP based on prior reports 
of mitochondrial staining.  Petit et al. reported that the uptake of the fluorochrome 
Rhodamine 123 into mitochondria was reduced in pre-apoptotic cells [27].  The authors 
found that the fluorophore accumulated into the mitochondrial membrane matrix space in 
inverse proportion to m in a Nernst fashion, and thus proposed that the reduced dye 
uptake was due to the m dissipation.  Moreover, Perry et al. reported that 
depolarization of m caused lower concentration of Rhodamine 123 in mitochondria, 
and vice versa. [28].  MitoRed is a cell membrane permeable Rhodamine-based dye that 
localizes in mitochondria and emits red fluorescence.  The interaction of MitoRed with 
mitochondria depends on the membrane potential of mitochondria.  Thus, the reduced 
mitochondrial staining of MitoRed strongly suggests that DOTAP in the proposed 
formulation of our project causes pre-apoptosis of A549 by dissipating the 
mitochondria’s inner transmembrane potential. 
All formulations containing cationic lipid DOTAP increased the uptake and 
intranuclear accumulation of Hoechst 33342.  Faleiro et al. found that caspase-9, which is 
activated earlier than caspase-3, directly or indirectly increases permeability of nuclear 
pores.  This increment allows caspase-3 and other molecules that could not pass through 
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nuclear pores in living cells to enter or leave the nucleus during apoptosis by diffusion 
[29].  Therefore, the increased nuclear staining by Hoechst 33342 in cells treated with 
formulations with DOTAP again attests DOTAP’s apoptotic effect on the A549 cells. 
It is not totally clear whether Alexa 488-labeled CytC is outside or inside of A549 
cells.  This can be resolved as future work by using confocal microscopy with higher 
magnification.  In addition, membrane impermeable fluorescent quenchers can be applied 
to the outside of such cells to test whether the fluorescence of Alexa 488-labeled CytC 
can be changed: a reduction of the fluorescence would indicate the formulation is still on 
the cell surface and vice versa. 
4.5.2 Cell Viability Assay 
Our data showed that free CytC caused the strong cytotoxicity, which is intriguing 
in the context of prior reports on CytC’s effects on cell viability.  Among earlier 
investigations, Piel et al. found that after intravenous injection in a septic mice model, 
bovine heart CytC was taken up by cardiomyocytes and significantly improved 
cardiomyocytes’ mitochondrial function.  Further, the survival rate of the cardiomyocytes 
increased from 15% to about 50% in the septic mice that received CytC injections [20], 
[21].  These findings may seem puzzling because CytC not only has to be taken up by 
cells, but also must translocate across the cell membrane to accumulate in mitochondria.  
This is now better explained by Jones et al, who showed that CytC contains cell 
penetrating peptide (CPP) epitopes in the N- and C-terminal helices [26].  Such CPPs can 
mediate the cellular uptake of various proteins.  Therefore, cytotoxicity of free Alexa 
488-labeled CytC needs to be evaluated in the future to validate whether the conjugated 
Alexa 488 moiety hindered CPPs in the N-terminal helices of CytC. 
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Nevertheless, another question needs to be addressed: why does the treatment 
with exogenous CytC, which will be taken up into the cytosol first, not amplify the 
apoptotic cascade but instead lead to increased survival of the cardiomyocytes in septic 
mice?  This phenomenon conforms with our data that lower cytotoxicity was found from 
CytC LP/MgP than from bare LP with or without MgP.  There were three likely 
interpretations.  First, cationic lipid DOTAP changes mitochondrial membrane potential, 
generates reactive oxygen species (ROS), dissociates CytC from the inner mitochondrial 
membrane, forms the mitochondrial outer membrane permeabilization pore (MOMPP), 
releases CytC from mitochondria, and induces apoptosis in different cell lines, all of 
which confirmed by Aramaki et al. [15].  The release of endogenous CytC, which is an 
essential component of the electron transport chain (ETC leads to mitochondrial 
dysfunction.  It has long been known that isolated mitochondria can reversibly release 
and take up CytC, while the latter restores mitochondrial function, as demonstrated by 
Jacobs and Sanadi [19], Doran and Halestrap [32].  Thus, exogenous CytC delivered by 
CytC LP/MgP in the cytosol could enter mitochondria to restore ETC activity of 
mitochondria and thus increase the cell viability.  This explanation was supported by the 
aforementioned studies of an animal model for sepsis [20], [21]. 
As the second interpretation, Zhivotovsky et al. and Li et al. reported that CytC-
induced apoptosis is dependent on the concentration of the cytosolic CytC [30], [31].  
Clayton et al. explained that endogenous CytC release occurs proportionally to the extent 
of cellular ‘stress’, and each cell, even from the same cell line, responds to a certain 
threshold of the released CytC to progress into apoptosis [23].  Zhivotovsky et al. found 
that microinjected 10 µM or 20 µM CytC could induce apoptosis in various cell types, 
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and this effect was dependent on the cytosolic CytC concentration.  Nevertheless, the 
apoptotic effect of 20 µM exogenous CytC was totally reversed when rat kidney (NRK) 
epithelial cells were transfected to express Bax/Bak, which are members of Bcl-2 family 
proteins known to induce formation of MOMPP (Fig. 4.7.) [30].  In this case, the 
exogenous CytC entered mitochondria through MOMPP by active transport [32], leading 
to a great decrement of cytosolic CytC concentration and protection of MOMPP-
expressing cells from apoptosis.  Cationic lipid DOTAP also leads to formation of the 
mitochondrial outer membrane permeabilization pore (MOMPP) [15].  Therefore, after 
the cells were exposed to CytC LP/MgP, DOTAP would induce MOMPP formation in 
the affected pre-apoptotic cells, followed by a translocation of the exogenous cargo 
protein CytC from the cytosol into the mitochondria.  This would then protect the 
DOTAP-injured cells from entering apoptosis, resulting in higher cell viability. 
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Fig. 4.7. Effect of CytC microinjection in normal rat kidney (NRK) epithelial cells. Wild-
type cells were injected with 20 µM (dark red) or 10 µM (green) CytC.  Cells expressing 
MOMPP were injected with 20 µM CytC (orange) [30]. 
 
 
 
As the third possible interpretation, free CytC also functions as a universal radical 
scavenger within the mitochondrial inner-membrane space.  Because CytC constantly 
undergoes oxidation/reduction cycles in a respiring cell, it contributes to detoxification 
reactions against superoxide and hydrogen peroxide [22].  It is known that cationic lipid 
DOTAP enhances generation of reactive oxygen species (ROS), which eventually 
induces apoptosis [15].  Exogenous CytC delivered by CytC LP/MgP in the cytosol may 
act as a ROS scavenger like catalase, which removes DOTAP-generated ROS, and rescue 
cells from DOTAP-induced apoptosis. 
Although the mechanism is still unclear, CytC decreases cytotoxicity of cationic 
lipids, which will facilitate the pharmaceutical applications of the latter in drug delivery 
systems. 
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4.6 Conclusion 
CytC LP/MgP successfully led to the attachment of CytC to A549 cells.  
Intracellular delivery of CytC alleviated the cytotoxicity of cationic lipids in A549 cells, 
which could facilitate the clinical use of cationic lipids in drug delivery systems.
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